Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.69 |
| ▸ | BRD2 | P25440 | 5/20 | 0.67 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.67 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12098991 | 0.92 | BRD4 (0.81) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098673 | 0.91 | BRD4 (0.81) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098574 | 0.90 | BRD4 (0.70) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18904315 | 0.89 | BRD4 (0.70) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12099187 | 0.88 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098944 | 0.88 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098719 | 0.87 | BRD4 (0.66) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12099289 | 0.86 | BRD4 (0.69) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098996 | 0.86 | BRD4 (0.67) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18904313 | 0.86 | BRD4 (0.70) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496576-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 5/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.